Key Stats for RCUS Stock
- Price Change for RCUS stock: +17.5%
- RCUS Share Price as of March 02: $24
- 52-Week High: $26
- RCUS Stock Price Target: $34
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Arcus Biosciences (RCUS) stock climbed 17.5% this week and now trades at $24, just below its 52-week high of $26.40. The move followed the company’s Q4 2025 earnings release and pipeline updates in late February. Investors also reacted to new clinical data for casdatifan in late-line kidney cancer.
Reuters reported that Arcus posted a Q4 net loss of $106 million, which was up 12.8% year over year. Q4 operating expenses totaled $147 million, reflecting continued investment in its oncology pipeline. Revenue declined in the quarter, and net losses widened as development costs increased.
At the same time, Arcus filed for a mixed shelf offering on February 26. While shelf filings can raise dilution concerns, the company maintains a strong liquidity position. Total cash and short-term investments stood at $981 million at year-end.
The company also announced upcoming presentations at the Leerink Global Healthcare Conference and the Barclays Global Healthcare Conference in March. With Q1 2026 results expected on May 7, investors appear focused on both pipeline progress and balance sheet strength.
See analysts’ growth forecasts and price targets for RCUS stock (It’s free!) >>>
What the Market Is Telling Us About RCUS Stock
The rally suggests investors are placing value on Arcus’ clinical assets rather than near-term earnings. The company remains unprofitable, with a net loss of $353 million over the last twelve months. Operating margins were negative 156.3%, reflecting heavy R&D investment.
However, Arcus holds $981 million in cash and short-term investments against total liabilities of $508 million. LTM net debt is negative $791 million, indicating a net cash position. That liquidity provides runway to advance late-stage programs.
Arcus continues to advance casdatifan and domvanalimab across multiple indications. Recent data from the ARC-20 study showed a 15.1-month median progression-free survival for casdatifan in kidney cancer. Those results helped shift sentiment despite widening quarterly losses.
Market data also reflects growing interest. The company’s market cap is approximately $3 billion, and shares outstanding total 125.35 million. With a 5-year beta of 0.84 and an average 3-month volume of 1.57 million shares, trading activity has accelerated in recent news.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Arcus Biosciences, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up RCUS, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track RCUS alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Arcus Biosciences stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
